Candel Therapeutics Falls 26% on Mid-2027 BLA Plan and New $50M Stock Program
Candel closed Friday at $6.20, 26.1% below Thursday, after a mid-2027 BLA target and a new $50 million at-the-market stock program. Shares rose 18.1% in the regular session from the pre-market close.

Candel Therapeutics, Inc. (NASDAQ: CADL) said in its third-quarter report, filed with the SEC at 4:05 p.m. ET on Thursday, Nov. 12 (after-hours trading), that it now plans to submit a Biologics License Application (BLA, the request for FDA approval) for prostate cancer drug aglatimagene in mid-2027. A prospectus supplement filed at 4:22 p.m. ET set up an at-the-market offering of up to $50 million in common stock through Jefferies.
A later BLA date and more shares for sale hit the stock
The two items reached the SEC within minutes of each other, so the drop cannot be assigned to one. The company said the mid-2027 date is pending its dialogue with the FDA. Cash of $203.1 million is expected to fund operations into the second quarter of 2028, according to the results release.
A 39% after-hours plunge, partly reversed on Friday
Candel closed Thursday at $8.39, down 9% on the day. That decline came before the 4:05 p.m. ET filing, and it is not clear what drove it. In after-hours trading (the session after the 4:00 p.m. close), the stock fell 39.09% to $5.11.
Friday's pre-market session (before the 9:30 a.m. open) ended at $5.25, up 2.73% from the after-hours close, on 471,580 shares. The regular session ranged from $5.19 to $6.63 and ended at $6.20, up 18.1% from the pre-market close and down 26.1% from Thursday's close. Volume was 5.85 million shares, 5.49 times the 10-day average pace.
In after-hours trading on Friday, shares were at $6.00, down 3.23% from the close, as of 4:45 p.m. ET, on volume of 46,429 shares.
Before the news, the stock had gained 8.83% on Nov. 6 and 8.46% on Nov. 9, closing that day at $9.49. From Oct. 15 to Nov. 12, shares fell 5.84%.
What the company said, and what the program adds
The company said the BLA date reflects timelines tied to certain assay refinement (an assay is a lab test). Canaccord Genuity maintained its Buy rating on Friday and lowered its price target to $13.
The offering adds potential supply. Candel said in the prospectus supplement that it has sold the full $50 million available under its prior agreement with Jefferies, which it amended and restated on Nov. 12. The new agreement allows sales of up to another $50 million at prices set by market conditions, with a 3.0% commission to Jefferies. Jefferies is not required to sell any set amount.
Candel's market value is about $460 million, with a float (shares available to trade) of about 65.31 million. Average daily volume is about 1.32 million shares.
Loss widened, with spending tied to launch preparation
Analysts had expected a third-quarter loss of $0.35 per share. Candel reported a loss of $0.28.
- Net loss: $21.9 million, against $11.3 million a year earlier.
- Research and development expense: $15.6 million, up from $8.5 million, on higher clinical trial, manufacturing and employee costs.
- General and administrative expense: $7.4 million, up from $4.7 million, on higher employee costs and commercial readiness.
- Cash: $203.1 million at Sept. 30.
The company said it has run a process validation campaign at its contract manufacturer. The batches are being tested and are intended for commercial use if the BLA is approved. It also added a regulatory and quality executive to its board and named a new general counsel.
Clinical updates came from the Society for Immunotherapy of Cancer meeting. Data from the PrTK05 phase 2 trial showed systemic activation of CD8 T cells (immune cells that kill other cells) after aglatimagene treatment. For linoserpaturev in recurrent high-grade glioma, median overall survival in 50 patients was 12.0 months.
Dates and milestones ahead
- Mid-2027: planned BLA submission for aglatimagene, pending the FDA dialogue.
- Biodistribution and shedding data from the PrTK05 trial, which the company said remain on track (no date given).
- Testing results for the validation batches intended for commercial use.
- Q2 2028: the point to which the company says its cash funds the current operating plan.
Bottom line
Candel now has a mid-2027 BLA target, a new $50 million at-the-market program and cash the company says lasts into the second quarter of 2028. Shares rebounded in Friday's regular session but closed at $6.20, below Thursday's $8.39.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




